Chemotherapy with MECOP-B for intermediate-grade and high-grade non-hodgkin’s lymphoma in Saudi Arabia: Clinical results and analysis of prognostic factors

Acta Haematologica

Volumn 96, Issue 3, 1996, Pages 126-134

  Ibrahim, Ezzeldin M ^a   Bunyan, Reem F ^a   Al Mulhim, Fatma A ^a   Al Nabhan, Arwa A ^a   Ibrahim, Rania E ^b  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b The American University in Cairo   (Egypt)

Author keywords

Fetal stem cells; Human fetuses; Immunological tolerance; In utero transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FOLINIC ACID; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; SEROTONIN 3 ANTAGONIST; VINCRISTINE;

ADULT; AGE; AGED; ALOPECIA; ARTICLE; AVASCULAR NECROSIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NEUROPATHY; NEUTROPENIA; NONBIOLOGICAL MODEL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SAUDI ARABIA; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SAUDI ARABIA; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0029758416     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203743     Document Type: Article

References (36)

1. Amer MH: Pattern of cancer in Saudi Arabia: A personal experience based on the management of 1000 patients. King Faisal Specialist HospMedJ 1982;2:202-215.
2. El-Akkad S: Cancer in Saudi Arabia: A comparative study. Saudi Med J 1983;4:156-164.
3. Ibrahim EM, Satti MB, Al-Idrissi HY, Abdel Satir A, Al-Mohaya SA, Al-Qourain A, Al-Frei-hi H, Abssod GH: Combination chemotherapy only of stage I and II non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 1986;22:199-203.
4. Ibrahim EM, Satti MB, Al-Idrissi HY, Al-Mul-him FA, Abssod GH, Adel Jabar A: Non-Hodg-kin’s lymphoma in Saudi Arabia: Prognostic factors and an analysis of the outcome of the combination chemotherapy only, for both localized and advanced disease. Eur J Cancer Clin Oncol 1988;24:391-401.
5. Ibrahim EM, Al-Idrissi HY: MECOP-B regimen in the management of non-Hodgkin’s lymphoma: Preliminary analysis of prognostic factors and total dose-intensity. Cancer J 1989;2: 444-449.
6. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985;102:596-602.
7. The Non-Hodgkin’s Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphoma: Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
8. Carbone PP, Kaplan HS, Musshoft K, Smitilers DW, Tubiana M: Report of the Committee on Hodgkin’s Disease's Staging Classification. Cancer Res 1971;31:1860-1861.
9. Cox DR, Snell EJ: Analysis of Binary Data, ed 2. London, Chapman & Hall, 1989.
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
12. Cox DR, Oakes D: Regression models and life tables (with discussion). J R Stat Sect 1972; B34:187-220.
13. Dixon WJ, Brown MB, Engleman L, Jennrich RI: BMDP Statistical Software. Berkeley University of California Press, 1990.
14. Oken MM, Creech RH, Tormey DC: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5: 649-655.
15. Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffc ES, Cossman J, Fisher RI, Young RC: Superiority of ProMACE-CytaBOM over ProMace-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991;9:25-38.
16. Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, Ding JC, Dart G, Matthews J, Firkin FC, Lowcnthal RM, Ironside P (Australian and New Zealand Lymphoma Group): Randomized comparison of MACOP-B with CHOP in patients with intermediatc-grade non-Hodgkin’s lymphoma. J Clin Oncol 1994;12:769-778.
17. Costa MA, Rabinowits M, Froimtchuk MJ, Ol-ivatto LO, Allan SE, Gil RA, Andrade CA, Martino JL, Dobbin JA, Carrico MK: Longterm results with MACOP-B in the treatment of aggressive non-Hodgkin’s lymphomas. The experience in Brazil. Am J Clin Oncol 1994,17: 323-327.
18. Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coscr P, Porcellini A, Vespignani M, Capnist G. Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio LP, Perrotta A, Rosso R, Damasio E, Rizzoli V: MACOP-B versus Pro-MACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Group. J Clin Oncol 1994; 12:1366-1374.
19. National Cancer Institute: Common Toxicity Criteria. Bethesda, NCI, 1988.
20. O’Reilly SE, Hoskins P, Klimo P. Connors JM: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin’s disease. Ann Oncol 1991;2(suppl 1): 17-23.
21. Ang PT, Soh LT, Sng I, Chua EJ, Ong YW: MACOP-B in advanced non-Hodgkin’s lymphoma. Am J Clin Oncol 1993;16:315-318.
22. Dclmcr A. Bauducr F, Ruskone-Fourmestraux A, Ajchcnbaum-Cymbalista F, Delmas-Mar-salet B, Rio B, Marie JP. Zittoun R: Treatment of high malignancy lymphoma with intensive short-term chemotherapy using the MACOP-B regimen. Cancer Paris 1993;80:808-815.
23. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM. Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002-1006.
24. Connors JM, Klimo P: MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional oberva-tions. Semin Hematol 1988;25(suppl):41-46.
25. O'Reilly SE, Connors JM: Is there a role for MACOP-B in the treatment of diffuse large cell lymphoma? Leuk Lymphoma 1993;10(suppl): 85-89.
26. Cersosimo RJ, Ki Hong W: Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an Adriamycin analogue. J Clin Oncol 1986;4:425-439.
27. Brugiatelli M, Federico M. Gobbi PG, Avan-zini P. Callea V, Cavanna L, De Pasquale A, Di Prisco AV, Di Rienzo N, Silingardi V: Epi-doxorubicin vs. idarubicin containing regimens in intermediate and high grade non-Hodgkin’s lymphoma: Preliminary results of a multicentric randomized trial. Hematologica 1993;78:305-312.
28. Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS. Rosenthal DS, Skarin AT, Canellos GP: The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990;8:84-93.
29. Fisher RI, DcVita VT Jr. Hubbard SM, Longo DL. Wesley R. Chabner BA. Joung RC: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983;98:304-309.
30. Goldie JH, Coldman AJ, Gudanskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;65:439-449.
31. Meyer RM, Hryniuk WM, Goodyear MDE: The role of dose intensity in determining outcome in intermediate-grade NHL. J Clin Oncol 1988;9:339-347.
32. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
33. Ibrahim EM, Al-Idrissi HY, Al-Khattii AA, Al-Faraj AA, Al-Gindan Y, Al-Khatib RI, Al-Kha-rouf JA: Piperacillin combined with aminoglycoside for empirical therapy of febrile granulocytopenic cancer patients. Cancer Ther Control 1990;1:205-211.
34. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M. Skelton J. Thaler M, Wesley R: A randomized trial comparing ceftazidime with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl Med 1986;315:552-558.
35. The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-1698.
36. Ibrahim EM, Uwaydah A, Al-Mulhim F, Ibrahim AW, Al-Hassan AY: Tuberculosis in patients with malignant disease. Indian J Cancer 1989;26:53-57.